Prognostic factors in patients with minor salivary gland carcinoma of the oral cavity and oropharynx

Head & Neck ◽  
2010 ◽  
Vol 33 (10) ◽  
pp. 1406-1412 ◽  
Author(s):  
José F. Carrillo ◽  
Federico Maldonado ◽  
Liliana C. Carrillo ◽  
Margarita C Ramirez-Ortega ◽  
Juan G. Gómez Pizano ◽  
...  
2009 ◽  
Vol 123 (S31) ◽  
pp. 52-57 ◽  
Author(s):  
H Chijiwa ◽  
K Sakamoto ◽  
H Umeno ◽  
T Nakashima ◽  
G Suzuki ◽  
...  

AbstractThis paper reviews 22 cases of minor salivary gland carcinoma of the oral cavity or oropharynx which were treated at Kurume University Hospital between 1976 and 2005. Minor salivary gland carcinoma was observed in eight of 362 patients with cancer of the oral cavity (2 per cent), and in 14 of 275 patients with cancer of the oropharynx (5 per cent). The five-year and 10-year survival rates of patients with oropharyngeal minor salivary gland carcinoma were 90 per cent. No statistically significant difference was observed between survival rates for oropharyngeal minor salivary gland carcinoma and for oropharyngeal squamous cell carcinoma (p = 0.06). The five- and 10-year survival rates of patients with oral cavity minor salivary gland carcinoma were 75 and 37 per cent, respectively. No statistically significant difference was observed between survival rates for oral cavity minor salivary gland carcinoma and oral cavity squamous cell carcinoma.Patients' survival results correlated well with the clinical stage of their lesions. A significant difference in survival was observed, comparing stage IV with stages I, II and III (p = 0.04). In contrast, no significant relationship was found between either survival and tumour type or survival and treatment. Adjuvant therapy is recommended for patients with grade III adenoid cystic carcinoma with perineural infiltration or intravascular infiltration.


2009 ◽  
Vol 141 (3) ◽  
pp. P164-P164
Author(s):  
Kiran Kakarala ◽  
Neil Bhattacharyya

2010 ◽  
Vol 143 (1) ◽  
pp. 122-126 ◽  
Author(s):  
Kiran Kakarala ◽  
Neil Bhattacharyya

2017 ◽  
Vol 158 (2) ◽  
pp. 287-294 ◽  
Author(s):  
Alexander N. Goel ◽  
Karam W. Badran ◽  
Adam P. G. Braun ◽  
Alexander M. Garrett ◽  
Jennifer L. Long

Objective We sought to describe the patient, tumor, and survival characteristics of minor salivary gland carcinoma (MSGC) of the oropharynx using a large, population-based database. Study Design Cross-sectional analysis of the National Cancer Institute’s SEER database (Surveillance, Epidemiology. and End Results). Subjects and Methods We reviewed the SEER database for all cases of MSGC of the oropharynx from 1988 to 2013. Relevant demographic, clinicopathologic, and survival variables were extracted and analyzed. Cox multivariate regression was performed to identify prognostic factors. Results We identified 1426 cases of MSGC of the oropharynx (mean age, 58 years; 51% female). The soft palate (39.2%) and base of tongue (38.6%) were the most commonly involved sites. The most common histologic subtypes were mucoepidermoid carcinoma (32.1%), adenocarcinoma (25.9%), and adenoid cystic carcinoma (23.3%). Five- and 10-year rates of disease-specific survival were 75.1% and 61.6%, respectively. Independent prognostic factors included tumor grade, T stage, N stage, and age >70 years. Conclusions This study represents the largest multivariate survival analysis of MSGC of the oropharynx to date. Independent prognosticators include tumor grade, T stage, N stage, and age.


2020 ◽  
pp. 019459982093832
Author(s):  
Ling-feng lan ◽  
Chen-kai Gao ◽  
Chao-wu Ma

Objective Minor salivary gland carcinoma (MiSGC) is rare, and the understanding of this disease is insufficient. This study aimed to identify independent risk factors and develop a nomogram for evaluating the overall survival (OS) and cancer-specific survival (CSS) of patients with MiSGC. Study Design Retrospective cohort study. Setting SEER database (Surveillance, Epidemiology, and End Results). Subjects and Methods We collected data from patients diagnosed with MiSGC between 2004 and 2015 from the SEER database. According to patient registration, all patients were randomly allocated to training sets and validation sets (2:1). Then, Kaplan-Meier product limit curves and Cox proportional hazard regressions were performed to estimate the prognostic effect of variables. Nomograms based on Cox proportional hazard regressions were established to estimate 3- and 5-year OS and CSS. Finally, the nomogram was developed by the training set, and validation was performed with the concordance index, calibration curves, and decision curve analyses. Results In total, 1787 MiSGC cases were registered in SEER. The concordance index for internal validation of OS and CSS prediction was 0.842 and 0.816; that of external validation was 0.871 and 0.831. The calibration plots showed good consistency between nomogram prediction and actual survival. The decision curve analysis showed substantial net benefits of the new predictive model. Conclusions We constructed nomograms and a corresponding risk classification system predicting the OS and CSS of patients with MiSGC. These tools can generate simple-to-use clinical risk grouping and determine the relationship between adjuvant therapy and active surveillance.


2009 ◽  
Vol 119 (7) ◽  
pp. 1334-1338 ◽  
Author(s):  
Marco Cianchetti ◽  
Pamela S. Sandow ◽  
Lauren D. Scarborough ◽  
Christopher G. Morris ◽  
Jessica Kirwan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document